Novavax (LTS:0UP6) Short-Term Debt : $0 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Novavax Short-Term Debt?

Novavax's Short-Term Debt for the quarter that ended in Mar. 2024 was $0 Mil.

Novavax's annual Short-Term Debt increased from Dec. 2021 ($0 Mil) to Dec. 2022 ($325 Mil) but then declined from Dec. 2022 ($325 Mil) to Dec. 2023 ($0 Mil).

Novavax Short-Term Debt Historical Data

The historical data trend for Novavax's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novavax Short-Term Debt Chart

Novavax Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt

Get a 7-Day Free Trial

324.88

Novavax Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Short-Term Debt	Get a 7-Day Free Trial															-	-	-	-	-

Novavax Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Novavax Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Novavax's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Novavax (LTS:0UP6) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novavax Inc (LTS:0UP6) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

NVAX:USA NVAX:Mexico NVV1:Germany

Address

21 Firstfield Road, Gaithersburg, MD, USA, 20878

Website

https://www.novavax.com

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. Novavax develops product candidates geared toward all age demographics of the general population.

Novavax (LTS:0UP6) Headlines

No Headlines